Antibodies to Infliximab in Patients Treated with Either the Reference Biologic or the Biosimilar CT-P13 Show Identical Reactivity Towards Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease
2017
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI